A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naive patients with progressive metastatic castration resistant prostate cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Ipilimumab (Primary) ; Abiraterone acetate; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
- 07 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 10 Jun 2017 Biomarkers information updated